Mukesh Ambani's Reliance withdraws Operation Sindoor trademark application, says it was filed…
In a statement, Reliance stated that it has no intention of trademarking 'Operation Sindoor,' a phrase which is a powerful symbol of Indian bravery and a part of the national consciousness.
'Jio Studios, a unit of Reliance Industries, has withdrawn its trademark application, which was filed inadvertently by a junior person without authorisation,' it said.
Earlier, four applications, including one by Reliance, were filed with the Office of the Controller General of Patents, Designs & Trade Marks on Wednesday, seeking to use the phrase for entertainment-related services like audio and video content.
All four applicants filed between 10.42 am and 6.27 pm on May 7 for registration under Class 41 of the Nice Classification, which includes education and training services, film and media production, live performances and events, digital content delivery and publishing, and cultural and sporting activities.
This category is often used by OTT platforms, production houses, broadcasters, and event companies, suggesting that 'Operation Sindoor' could have become a film title, web series or documentary brand.
Reliance filed the application for entertainment, publishing, and language training, according to the scope of application claimed by the applicants shown on the Controller General of Patents, Designs and Trade Marks.
The Mukesh Ambani-run firm was the first to apply for a patent on Wednesday and was followed by three more – a Mumbai resident, a retired Indian Air Force officer and a Delhi-based lawyer.
'Reliance Industries and all its stakeholders are incredibly proud of Operation Sindoor, which came about in response to a Pakistan-sponsored terrorist attack in Pahalgam,' the statement said.
'Operation Sindoor is the proud achievement of our brave Armed Forces in India's uncompromising fight against the evil of terrorism.'
Reliance, it said, stands fully in support of the government and Armed Forces in this fight against terrorism. 'Our commitment to the motto of 'India First' remains unwavering.'
(With Inputs From PTI)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
25 minutes ago
- Mint
Zydus Life beats Street in Q1, eyes biosimilars boost in US
Zydus Lifesciences beat Street estimates in the June quarter on the back of steady India growth, a stronger US portfolio, and surging international sales. This sets the stage for its biosimilars push in the world's largest pharmaceuticals market following a $125 million manufacturing acquisition. The Ahmedabad-based drugmaker reported a revenue growth of 6% year-on-year (y-o-y) to ₹ 6,573 crore, and a net profit of ₹ 1,466 crore, up 3%. Its Ebitda was ₹ 2,088 crore, with the margin at 31.8%. A Bloomberg poll had pegged its revenues at ₹ 6,477 crore and profit after tax at ₹ 1,332 crore. In the June quarter, Zydus's India business clocked an 8% y-o-y growth, driven by chronic therapies and innovation-led portfolio expansion. Its US business, the largest revenue driver for the company, grew 2.9%. The company's international business segment, which includes Europe and other emerging markets, grew 36.8% y-o-y on the back of strong demand and has emerged as a 'reliable third pillar of growth,' said Sharvil Patel, the company's managing director. Zydus, which has a significant portfolio of biosimilars in India and other markets, is eyeing growth in the US on the back of easing regulations and a recent acquisition of two US-based two biologics contract manufacturing facilities. '...the regulatory scenario has changed for certain classes of biosimilars, there is no longer a requirement for an efficacy trial. So the pathway has become much better for the US,' Patel told investors in a post-earnings call on Tuesday. 'The second factor is that we have a manufacturing footprint now in the US to make biologics,' he added. The company is looking at either an in-house portfolio or licensing deals with manufacturing firms in the US to add one or two biosimilars, Patel said. Zydus acquired two biologics contract development and manufacturing organization (CDMO) plants in California from US-based Agenus Inc for a total consideration of up to $125 million in June. It also acquired a 5.9% stake in Agenus Inc for $16 million. Agenis is a clinical stage immuno-oncology company committed to developing immune therapies to combat cancer. 'The acquisition marks our strategic investment in the US-based manufacturing for biologics, thereby adding a sustainable growth driver for the future,' Patel said. The company has 14 launched biosimilars and 10 in the pipeline, and a presence in India and as well as in the international markets. Zydus is foraying into new avenues of growth such as medtech, and is also strengthening its specialty business play to unlock value. The company has been enriching its portfolio of 505 b(2) specialty products, which will be a significant profitability driver, going forward, Patel said. 'We already have a decent revenue on 505 b(2) with good profitability, but we are seeing a major scale-up in FY27 and beyond,' he said. 505 b(2) products refer to drug candidates that may be new indications or new combinations, and are approved through the 505 b(2) application, as opposed to an Abbreviated New Drug Application (ANDA) in the US FDA.
Economic Times
25 minutes ago
- Economic Times
ET Market Watch: Banking blues drag stock markets; Nifty eyes 24,700 retest
Transcript Markets took a breather after Monday's rally. Indian benchmark indices ended lower in a choppy Tuesday trade, dragged by banking heavyweights HDFC Bank and ICICI 80,235, down 368 pts (-0.5%)Nifty: 24,487, down 98 pts (-0.4%)Top Nifty Gainers: Tech Mahindra, Maruti Suzuki, Hero MotoCorp, M&M, NTPCTop Losers: Bajaj Finance, Trent, Hindustan Unilever, Nestle India, EternalSector CheckBanks & Financials were the big drags. Nifty Bank down 0.84%, Nifty Financials down 0.9%.On the upside, Auto, IT, Pharma & Oil & Gas gained up to 0.7%.Expert TakeAs per Nagaraj Shetti, Senior Technical Research Analyst at HDFC Securities: Nifty formed a small red candle with a long upper shadow, indicating weak momentum to break 24,700. Support is seen at 24,300–24,400, and analysts expect a retest of 24,700 if support CuesAsian markets mostly in the green. Nikkei was down +0.65%, Hang Seng +0.77%.Europe mixed; FTSE 100 slightly higher, DAX down 0.4%.Currency WatchRupee slightly stronger at 87.64 against the USD; traders eye U.S. inflation data for Fed policy cues.
&w=3840&q=100)
First Post
25 minutes ago
- First Post
How investor confidence in India is at a record high
US President Donald Trump has announced a 50 per cent tariff on India for its continued trade relationship with Russia in the backdrop of the two countries negotiating a free trade agreement. (FTA). However, the data shows that investor confidence in India remains at a record high. But what happened? What do experts say? The Indian stock markets have rebounded from Trump's tariff announcement last week, which left many stunned and shaken. PTI US President Donald Trump's tariffs have roiled world markets. However, the data shows that investor confidence in India remains at a record high. Trump has announced a 50 per cent tariff on India for its continued trade relationship with Russia in the backdrop of the two countries negotiating a free trade agreement (FTA). New Delhi has hit back at Washington, accusing it and the West of hypocrisy for their dealings with Moscow and said that it will not compromise on the national interest. STORY CONTINUES BELOW THIS AD But what do we know? What does the data show? Let's take a closer look Markets rebound, SIPs on rise The Indian stock markets have rebounded from Trump's tariff announcement last week, which left many stunned and shaken. India's key equity indices on Monday rallied around 1 per cent. The BSE Sensex gained 746 points to close above the 80,000 mark with buying in oil, auto and banking shares amid fresh foreign fund inflows. Meanwhile, the 50-share NSE Nifty jumped by 221.75 points or 0.91 per cent to 24,585.05 . The Sensex had dropped 765.47 points or 0.95 per cent to settle at 79,857.79 on Friday and the NSE Nifty had dropped 232.85 points or 0.95 per cent to 24,363.30. This came after Trump's tariffs, which took effect on Thursday, shook markets. The FIIs also witnessed an exodus to the tune of Rs 4,997.19 crore on Thursday. Small investors don't seem perturbed by the Trump tariffs. Systematic Investment Plan (SIP) contributions touched a record high of Rs 28,464 crore in July – up four per cent from Rs 27,268.79 crore in June. This, according to data from the Association of Mutual Funds in India (Amfi) on Monday. The number of new SIPs also reached 6.86 million in July. That number was at 6.19 million in June and 5.91 million May. The number of contributing SIP accounts increased from 86.4 million in June 2025 to 91.1 million in July 2025. STORY CONTINUES BELOW THIS AD SIPs allow citizens to put fixed amounts of money in mutual funds at certain intervals. This encouraged investors to observe fiscal discipline as well as them gives them the long-term advantages of rupee-cost averaging (DCA). It also allows investors to build wealth over a longer period of time. They also tend to be popular with lay investors rather than the more informed lot. Meanwhile, monthly equity flows scaled the Rs 42,000 crore mark in July while the industry assets under management (AUM) crossed Rs 75 lakh crore in the same month, data from Amfi showed. Systematic Investment Plan (SIP) contributions touched a record high of Rs 28,464 crore in July – up four per cent from Rs 27,268.79 crore in June. Amfi chief Venkat N Chalasani said the development was a reflection of sustained investor confidence and disciplined participation. 'The total Assets under Management grew by 1.3 per cent to Rs 75.36 Lakh Crores, despite pressures from a strong US dollar and persistent foreign fund outflows. This is a testament to sustained investor confidence and disciplined participation,' Chalasani said. 'Equity mutual funds recorded their highest-ever monthly inflow of Rs 42,702 crore, with DIIs maintaining strong support. SIP contributions hit a new record of Rs 28,464 crore, and contributing accounts grew 5.4 per cent to 9.11 crore — clear evidence of disciplined investing even amid volatility'. STORY CONTINUES BELOW THIS AD What do experts say? Experts say SIPs could go past the Rs 30,000 crore mark soon. 'SIP numbers…could reach the ₹30,000-crore monthly milestone soon. This reflects growing investor maturity, rising financial awareness, greater digital access, and sustained market confidence. The resilience of the Indian markets, despite global uncertainties, is remarkable. Using corrections as opportunities is wise, but in the long run, systematic investing remains the most powerful approach,' Suranjana Borthakhur, head of distribution & strategic alliances, Mirae Asset Investment Managers (India), told Fortune India. They say SIPs are a key factor in stabilising the market. 'The steady growth in SIP inflows brings significant reassurance, as it helps reduce market volatility. We also view rising SIP investments as an early indicator of job creation and economic strength. The record-high monthly SIP inflow of ₹28,464 crore reflects a positive outlook for India's economy,' said Jyoti Prakash, managing partner–equity and PMS, AlphaaMoney, added. Aditya Birla CEO A Balasubramanian said the record inflow into equities and all-time high SIP contribution show the deep commitment and trust shown by the investors in mutual funds. STORY CONTINUES BELOW THIS AD India's future is bright Surveys abroad show that the future looks even brighter for India. A recent survey by Bank of America shows that US fund managers are growing more bullish on emerging markets (EM). Over a third of fund managers, 37 per cent, say they are now overweight on EM stocks. That's the highest number since February 2023. This shift is driven by concerns over elevated US stock valuations and optimism about China's economic rebound. Nearly half of investors, 49 per cent, say that EM equities are increasingly thought of as undervalued or cheap – the highest number in a year. Meanwhile, a massive 91 per cent of respondents think US equities are overvalued – mainly big tech firms, which they think have become the 'most crowded trade'. With inputs from agencies
